Abstract
AbstractSelective removal of molecular moieties from plasma of patients can result in tumor regression, auto-antibody clearance, and immune modulation. The ProsorbaRColumn consists of highly purified protein A isolated from Staphylococcus and covalently linked to inert silica housed in a polycarbonate device. Protein A acts as an immunoadsorbent to selectively remove immunoglobulin G (IgG) and IgG containing CIC via specific binding to the Fc fragment of IgG. Columns were sterile, disposable devices that remove approximately one gram of IgG from plasma per treatment. As part of a multicenter clinical trial, 8 of 22 (36%) end stage breast cancer patients exhibited objective antitumor responses. Treatment of 24 patients with immune thrombocytopenia resulted in 14 (58%) of patients having objective increases in platelet counts and clearance or significant reduction of anti-platelet antibody. The mechanism of action of this device is unknown at present but may be selective removal of IgG and CIC, and activation of factors such as the complement system which results in enhanced reticuloendothelial system (RES) clearance of CIC. In addition, immune modulation may result due to the stimulation of anti-idiotypic antibodies and selective clonal deletion of auto-antibody producing lymphocyte sub-populations.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
